ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements with these filters
Epigral Ltd reported revenue from operations of ₹736.2 Cr (+17.3% YoY) and net profit of ₹81 Cr (-6.8% YoY) for Q4 FY26.
Epigral Limited reported its FY2025-26 audited financial results. The company recommended a final dividend of Rs. 5.00 (50%) per equity share of face value Rs. 10. The standalone annual revenue stood at ₹2,527.18 Crore with a profit after tax of ₹333.01 Crore.
Epigral Limited has scheduled a Board Meeting for May 2, 2026, to approve audited standalone and consolidated financial results for the year ended March 31, 2026. The board will also consider a final dividend recommendation. The trading window remains closed until May 4, 2026.
Epigral Ltd has scheduled a Board Meeting for May 2, 2026. The directors will consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Additionally, the board will consider recommending a final dividend for the financial year.
Epigral Limited has issued a Postal Ballot notice to shareholders for the re-appointment of Mr. Sanjay Asher, Mr. Kanubhai Patel, and Mr. Raju Swamy as Independent Directors. Each re-appointment is for a second five-year term starting May 20, 2026. Voting concludes on May 19, 2026.
Epigral Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of three Non-Executive Independent Directors: Mr. Sanjay Asher, Mr. Kanubhai Patel, and Mr. Raju Swamy. Each re-appointment is for a second five-year term starting May 20, 2026. E-voting remains open from April 20 to May 19, 2026.
Epigral Ltd has approved the re-appointment of Mr. Sanjay Asher, Mr. Kanubhai Patel, and Mr. Raju Swamy as Non-Executive Independent Directors for a second five-year term effective May 20, 2026. These appointments remain subject to shareholder approval via postal ballot. The move ensures leadership continuity for the company's board through 2031.
Epigral Ltd reported net profit of ₹39.1 Cr (-62.4% YoY) for Q3 FY26.
Epigral Limited submitted a compliance certificate for the quarter ended March 31, 2026, as required under SEBI (Depositories and Participants) Regulations. The certificate from registrar MUFG Intime India confirms that securities received for dematerialisation were processed and listed on the stock exchanges within mandated timelines.